Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Trinity Biotech Secures $7M, Regains Nasdaq Compliance

14 August 2026 · By · Wire by Fusion42

Published

14 August 2026

Topic

operational-macro

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at stocktitan.net →

◆ Verified

Fusion42 · 14 August 2026 · Fusion42 review

Trinity Biotech secured an additional $7 million investment from Perceptive Advisors and regained compliance with Nasdaq's minimum bid price requirement, strengthening liquidity for its CGM+ platform and other strategic initiatives as it advances operational repositioning.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 14 Aug 2026 and 17 Aug 2026.

◆ ◆ The Wire takeaway

Trinity Biotech's regained Nasdaq compliance clears a critical hurdle for any Medtech founders tied to public markets, making it easier to raise capital or explore partnerships now that delisting risk is removed.

◆ Coverage

2 sources · first reported 14 Aug 2026 · latest 17 Aug 2026

◆ Related on Wire

◆ Topics

Medtechnasdaq-complianceequity-financingmedtechcontinuous-glucose-monitoringstrategic-repositioning